Form 4: Iovance Biotherapeutics Interim CEO Frederick Vogt Reports Stock Transactions

Frederick Vogt, Interim CEO & General Counsel of Iovance Biotherapeutics, reports acquisition and disposal of common stock and restricted stock units.

Summary

• On September 3, 2024, Frederick Vogt, Interim CEO & General Counsel of Iovance Biotherapeutics, engaged in transactions involving the company's common stock and restricted stock units (RSUs).
• Vogt acquired 10,417 shares of common stock upon vesting of RSUs and another 46,875 shares upon vesting of RSUs.
• He disposed of 4,426 shares and 19,913 shares of common stock to satisfy tax withholding requirements at a price of $10.85 per share.
• Following these transactions, Vogt beneficially owns 192,262 shares of common stock and 46,875 restricted stock units.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock transactions by an insider. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC when company insiders, like the CEO, trade in their company's stock. It provides transparency to the market about the transactions of company leadership.

Stakeholder Impact

• The transactions could have a minor impact on shareholders due to the change in the number of shares held by a company insider, but the impact is likely minimal given the nature of the transactions.

Key Dates